Immune globulin sulfonated human - KM Biologics/Teijin
Alternative Names: Dried sulfonated human immunoglobulin - KM Biologics/Teijin; Freeze-dried sulfonated human immunoglobulin; GGS-CIDP; GGS-MMN; GGS-MPA; GGS-ON; IVIG - KM Biologics/Teijin; KD-371; KD5-71; KD6-71; Kenketsu Venilon-I; Sulfonated human immunoglobulin; VenilonLatest Information Update: 01 Dec 2022
At a glance
- Originator Kaketsuken; Teijin
- Developer Kaketsuken; KM Biologics; Teijin
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Churg-Strauss syndrome; Infections; Optic neuritis
- Phase III Microscopic polyangiitis
- No development reported Motor neuron disease
- Discontinued Idiopathic pulmonary fibrosis; Multiple sclerosis
Most Recent Events
- 01 Dec 2022 No development reported - Preregistration for Motor neuron disease in Japan (IV) (NDR batch 26)
- 28 Nov 2022 Immune globulin sulfonated human is still in preregistration for Motor neuron disease in Japan (IV)
- 16 Jun 2021 Teijin completes a phase-III trial in Microscopic polyangiitis in Japan (IV, Infusion) (JapicCTI132394)